{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T21:09:56Z","timestamp":1774732196991,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,7,27]],"date-time":"2005-07-27T00:00:00Z","timestamp":1122422400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1007\/s00415-005-0934-5","type":"journal-article","created":{"date-parts":[[2005,7,25]],"date-time":"2005-07-25T21:55:45Z","timestamp":1122328545000},"page":"98-108","source":"Crossref","is-referenced-by-count":410,"title":["The window of therapeutic opportunity in multiple sclerosis"],"prefix":"10.1007","volume":"253","author":[{"given":"A. J.","family":"Coles","sequence":"first","affiliation":[]},{"given":"A.","family":"Cox","sequence":"additional","affiliation":[]},{"given":"E.","family":"Page","sequence":"additional","affiliation":[]},{"given":"J.","family":"Jones","sequence":"additional","affiliation":[]},{"given":"S. A.","family":"Trip","sequence":"additional","affiliation":[]},{"given":"J.","family":"Deans","sequence":"additional","affiliation":[]},{"given":"S.","family":"Seaman","sequence":"additional","affiliation":[]},{"given":"D. H.","family":"Miller","sequence":"additional","affiliation":[]},{"given":"G.","family":"Hale","sequence":"additional","affiliation":[]},{"given":"H.","family":"Waldmann","sequence":"additional","affiliation":[]},{"given":"D. A.","family":"Compston","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2005,7,27]]},"reference":[{"key":"934_CR1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0022-510X(99)00168-9","volume":"168","author":"Annunziata","year":"1999","unstructured":"Annunziata P, Lore F, Venturini E, Morana P, Guarino E, Borghi S, Guazzi GC (1999) Early synthesis and correlation of serum anti\u2013thyroid antibodies with clinical parameters in multiple sclerosis. J Neurol Sci 168:32\u201336","journal-title":"J Neurol Sci"},{"key":"934_CR2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ana.20045","volume":"55","author":"Bechtold","year":"2004","unstructured":"Bechtold DA, Kapoor R, Smith KJ (2004) Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 55:607\u2013616","journal-title":"Ann Neurol"},{"key":"934_CR3","doi-asserted-by":"crossref","first-page":"7278","DOI":"10.1523\/JNEUROSCI.19-17-07278.1999","volume":"19","author":"Brady","year":"1999","unstructured":"Brady ST, Witt AS, Kirkpatrick LL, de Waegh SM, Readhead C, Tu PH, Lee VM (1999) Formation of compact myelin is required for maturation of the axonal cytoskeleton. J Neurosci 19:7278\u20137288","journal-title":"J Neurosci"},{"key":"934_CR4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMoa011341","volume":"346","author":"Brex","year":"2002","unstructured":"Brex PA, Ciccarelli O, O\u2019Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346:158\u2013164","journal-title":"N Engl J Med"},{"key":"934_CR5","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/brain\/123.6.1102","volume":"123","author":"Broadley","year":"2000","unstructured":"Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA (2000) Autoimmune disease in first\u2013degree relatives of patients with multiple sclerosis. A UK survey. Brain 123:1102\u20131111","journal-title":"Brain"},{"key":"934_CR6","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1136\/jnnp.74.11.1551","volume":"74","author":"Chard","year":"2003","unstructured":"Chard DT, Brex PA, Ciccarelli O, Griffin CM, Parker GJ, Dalton C, Altmann DR, Thompson AJ, Miller DH (2003) The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. J Neurol Neurosurg Psychiatry 74:1551\u20131554","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"934_CR7","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1523\/JNEUROSCI.14-05-02594.1994","volume":"J Neurosci","author":"Colello","year":"1994","unstructured":"Colello RJ, Pott U, Schwab ME (1994) The role of oligodendrocytes and myelin on axon maturation in the developing rat retinofugal pathway. J Neurosci 14:2594\u20132605","journal-title":"J Neurosci"},{"key":"934_CR8","first-page":"464","volume":"44","author":"Coles","year":"1998","unstructured":"Coles AJ, Paolillo A, Molyneux PD, Wing M, Hale G, Miller DH, Waldmann H, Compston DA (1998) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 44:464","journal-title":"Ann Neurol"},{"key":"934_CR9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#","volume":"46","author":"Coles","year":"1999","unstructured":"Coles AJ, Wing M, Molyneux P, Paolillo A, Davie C, Hale G, Miller DH, Waldmann H, Compston A (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46:296\u2013304","journal-title":"Ann Neurol"},{"key":"934_CR10","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","volume":"354","author":"Coles","year":"1999","unstructured":"Coles AJ, Wing MG, Smith S, Corradu F, Greer S, Taylor CJ, Weetman AP, Hale G, Chatterjee KC, Waldmann H, Compston A (1999) Pulsed monoclonal antibody treatment and thyroid autoimmunity in multiple sclerosis. Lancet 354:691\u20131695","journal-title":"Lancet"},{"key":"934_CR11","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","volume":"357","author":"Comi","year":"2001","unstructured":"Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576\u20131582","journal-title":"Lancet"},{"key":"934_CR12","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","volume":"357","author":"Comi","year":"2001","unstructured":"Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576\u20131582","journal-title":"Lancet"},{"key":"934_CR13","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0140-6736(02)08220-X","volume":"359","author":"Compston","year":"2002","unstructured":"Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221\u20131231","journal-title":"Lancet"},{"key":"934_CR14","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","volume":"343","author":"Confavreux","year":"2000","unstructured":"Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430\u20131438","journal-title":"N Engl J Med"},{"key":"934_CR15","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/brain\/awg081","volume":"126","author":"Confavreux","year":"2003","unstructured":"Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770\u2013782","journal-title":"Brain"},{"key":"934_CR16","first-page":"81","volume":"110","author":"Cox","year":"2003","unstructured":"Cox AL, Thompson S, Hale G, Waldmann H, Compston DA, Coles AJ (2003) Lymphocyte depletion in multiple sclerosis induces a relative increase in regulatory T cells. Immunology 110, s1:81","journal-title":"Immunology"},{"key":"934_CR17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/brain\/117.1.49","volume":"117","author":"Davie","year":"1994","unstructured":"Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, McDonald WI (1994) Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 117:49\u201358","journal-title":"Brain"},{"key":"934_CR18","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1212\/WNL.57.8.1363","volume":"57","author":"Durelli","year":"2001","unstructured":"Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montanari E, Zaffaroni M (2001) Liver and thyroid function and autoimmunity during interferon\u2013beta 1b treatment for MS. Neurology 57:1363\u20131370","journal-title":"Neurology"},{"key":"934_CR19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0022-510X(01)00637-2","volume":"193","author":"Durelli","year":"2001","unstructured":"Durelli L, Oggero A, Verdun E, Isoardo GL, Barbero P, Bergamasco B, Brossa PC, Ghigo E, Maccario M, Faggiano F (2001) Thyroid function and antithyroid antibodies in MS patients screened for interferon treatment. A multicenter study. J Neurol Sci 193:17\u201322","journal-title":"J Neurol Sci"},{"key":"934_CR20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/brain\/120.3.393","volume":"120","author":"Ferguson","year":"1997","unstructured":"Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393\u2013399","journal-title":"Brain"},{"key":"934_CR21","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1212\/WNL.55.11.1714","volume":"55","author":"Filippi","year":"2000","unstructured":"Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G (2000) Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 55:1714\u20131718","journal-title":"Neurology"},{"key":"934_CR22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","volume":"82","author":"Gilleece","year":"1993","unstructured":"Gilleece MH, Dexter TM (1993) Effect of Campath\u20131H antibody on human hematopoietic progenitors in vitro. Blood 82:807\u2013812","journal-title":"Blood"},{"key":"934_CR23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1471-4159.2002.00973.x","volume":"82","author":"Golde","year":"2002","unstructured":"Golde S, Chandran S, Brown GC, Compston A (2002) Different pathways for iNOS\u2013mediated toxicity in vitro dependent on neuronal maturation and NMDA receptor expression. J Neurochem 82:269\u2013282","journal-title":"J Neurochem"},{"key":"934_CR24","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1126\/science.280.5369.1610","volume":"280","author":"Griffiths","year":"1998","unstructured":"Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, Schwab MH, Schneider A, Zimmermann F, McCulloch M, Nadon N, Nave KA (1998) Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 280:1610\u20131613","journal-title":"Science"},{"key":"934_CR25","first-page":"305","volume":"17","author":"Hale","year":"1996","unstructured":"Hale G, Waldmann H (1996) Recent results using CAMPATH\u20131 antibodies to control GVHD and graft rejection. Bone Marrow Transpl 17:305\u2013308","journal-title":"Bone Marrow Transpl"},{"key":"934_CR26","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","volume":"360","author":"Hartung","year":"2002","unstructured":"Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T (2002) Mitoxantrone in progressive multiple sclerosis: a placebo\u2013controlled, double\u2013blind, randomised, multicentre trial. Lancet 360:2018\u20132025","journal-title":"Lancet"},{"key":"934_CR27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1046\/j.1468-1331.2001.00196.x","volume":"8","author":"Heesen","year":"2001","unstructured":"Heesen C, Gbadamosi J, Schoser BG, Pohlau D (2001) Autoimmune hyperthyroidism in multiple sclerosis under treatment with glatiramer acetate \u2013 a case report. Eur J Neurol 8:199","journal-title":"Eur J Neurol"},{"key":"934_CR28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1034\/j.1600-0404.2000.101001036.x","volume":"101","author":"Heinzlef","year":"2000","unstructured":"Heinzlef O, Alamowitch S, Sazdovitch V, Chillet P, Joutel A, Tournier\u2013Lasserve E, Roullet E (2000) Autoimmune diseases in families of French patients with multiple sclerosis. Acta Neurol Scand 101:36\u201340","journal-title":"Acta Neurol Scand"},{"key":"934_CR29","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-0404.1998.tb01733.x","volume":"98","author":"Henderson","year":"1998","unstructured":"Henderson RD, Saltissi D, Pender MP (1998) Goodpasture\u2019s syndrome associated with multiple sclerosis. Acta Neurol Scand 98:134\u2013135","journal-title":"Acta Neurol Scand"},{"key":"934_CR30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF02334902","volume":"11","author":"Ioppoli","year":"1990","unstructured":"Ioppoli C, Meucci G, Mariotti S, Martino E, Lippi A, Gironelli L, Pinchera A, Muratorio A (1990) Circulating thyroid and gastric parietal cell autoantibodies in patients with multiple sclerosis. Ital J Neurol Sci 11:31\u201336","journal-title":"Ital J Neurol Sci"},{"key":"934_CR31","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1136\/bjo.79.11.1054","volume":"79","author":"Isaacs","year":"1995","unstructured":"Isaacs JD, Hale G, Waldmann H, Dick AD, Haynes R, Forrester JV, Watson P, Meyer PAR (1995) Monoclonal antibody therapy of chronic intraocular inflammation using Campath\u20131H3. Br J Ophthalmol 79:1054\u20131055","journal-title":"Br J Ophthalmol"},{"key":"934_CR32","first-page":"1103","volume":"23","author":"Isaacs","year":"1996","unstructured":"Isaacs JD, Hazleman BL, Chakravarty K, Grant JW, Hale G, Waldmann H (1996) Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH\u20131H. J Rheumatol 23:1103\u20131106","journal-title":"J Rheumatol"},{"key":"934_CR33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/rheumatology\/35.3.231","volume":"35","author":"Isaacs","year":"1996","unstructured":"Isaacs JD, Manna VK, Rapson N, Bulpitt KJ, Hazleman BL, Matteson EL, St. Clair EW, Schnitzer TJ, Johnston JM (1996) CAMPATH\u20131H in rheumatoid arthritis\u2013an intravenous dose\u2013ranging study. Br J Rheumatol 35:231\u2013240","journal-title":"Br J Rheumatol"},{"key":"934_CR34","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/0140-6736(92)92294-P","volume":"340","author":"Isaacs","year":"1992","unstructured":"Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, Waldmann H (1992) Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340:748\u2013752","journal-title":"Lancet"},{"key":"934_CR35","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/386724a0","volume":"386","author":"Kaplan","year":"1997","unstructured":"Kaplan MR, Meyer Franke A, Lambert S, Bennett V, Duncan ID, Levinson SR, Barres BA (1997) Induction of sodium channel clustering by oligodendrocytes. Nature 386:724\u2013728","journal-title":"Nature"},{"key":"934_CR36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ana.10443","volume":"53","author":"Kapoor","year":"2003","unstructured":"Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ (2003) Blockers of sodium and calcium entry protect axons from nitric oxide\u2013mediated degeneration. Ann Neurol 53:174\u2013180","journal-title":"Ann Neurol"},{"key":"934_CR37","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1046\/j.1365-2141.1997.612718.x","volume":"97","author":"Killick","year":"1997","unstructured":"Killick SB, Marsh JC, Hale G, Waldmann H, Kelly SJ, Gordon Smith EC (1997) Sustained remission of severe resistant autoimmune neutropenia with Campath\u20131H. Br J Haematol 97:306\u2013308","journal-title":"Br J Haematol"},{"key":"934_CR38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.nbd.2004.09.019","volume":"18","author":"Kotter","year":"2005","unstructured":"Kotter MR, Zhao C, van Rooijen N, Franklin RJ (2005) Macrophage\u2013depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis 18:166\u2013175","journal-title":"Neurobiol Dis"},{"key":"934_CR39","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1093\/brain\/awf235","volume":"125","author":"Kuhlmann","year":"2002","unstructured":"Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125:2202\u20132212","journal-title":"Brain"},{"key":"934_CR40","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1212\/WNL.60.1.44","volume":"60","author":"Leary","year":"2003","unstructured":"Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ (2003) Interferon beta\u20131a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 60:44\u201351","journal-title":"Neurology"},{"key":"934_CR41","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1365-2141.1993.tb03117.x","volume":"84","author":"Lim","year":"1993","unstructured":"Lim SH, Hale G, Marcus RE, Waldmann H, Baglin TP (1993) CAMPATH\u20131 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol 84:542\u2013544","journal-title":"Br J Haematol"},{"key":"934_CR42","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/qjmed\/89.12.903","volume":"89","author":"Lockwood","year":"1996","unstructured":"Lockwood CM, Thiru S, Stewart S, Hale G, Isaacs J, Wraight P, Elliott J, Waldmann H (1996) Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM 89:903\u2013912","journal-title":"QJM"},{"key":"934_CR43","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/brain\/119.6.2009","volume":"119","author":"Losseff","year":"1996","unstructured":"Losseff NA, Wang L, Lai HM, Yoo DS, Gawne Cain ML, McDonald WI, Miller DH, Thompson AJ (1996) Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119:2009\u20132019","journal-title":"Brain"},{"key":"934_CR44","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/bmj.300.6719.230","volume":"300","author":"Matthews","year":"1990","unstructured":"Matthews JN, Altman DG, Campbell MJ, Royston P (1990) Analysis of serial measurements in medical research. BMJ 300:230\u2013235","journal-title":"BMJ"},{"key":"934_CR45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"McDonald","year":"2001","unstructured":"McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg\u2013Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121\u2013127","journal-title":"Ann Neurol"},{"key":"934_CR46","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0896-6273(95)90172-8","volume":"15","author":"Meyer","year":"1995","unstructured":"Meyer Franke A, Kaplan MR, Pfrieger FW, Barres BA (1995) Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron 15:805\u2013819","journal-title":"Neuron"},{"key":"934_CR47","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/1531-8249(199912)46:6<850::AID-ANA7>3.0.CO;2-Q","volume":"46","author":"Miller","year":"1999","unstructured":"Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K (1999) Effect of interferon\u2013beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double\u2013blind, placebo\u2013controlled trial. European Study Group on Interferon\u2013beta1b in secondary progressive multiple sclerosis. Ann Neurol 46:850\u2013859","journal-title":"Ann Neurol"},{"key":"934_CR48","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/brain\/123.11.2256","volume":"123","author":"Molyneux","year":"2000","unstructured":"Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, Beckmann K, Dahlke F, Losseff N, Barker GJ, Thompson AJ, Miller DH (2000) The effect of interferon beta\u20131b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta\u20131b in secondary progressive multiple sclerosis. Brain 123:2256\u20132263","journal-title":"Brain"},{"key":"934_CR49","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/eje.0.1410325","volume":"141","author":"Monzani","year":"1999","unstructured":"Monzani F, Caraccio N, Meucci G, Lombardo F, Moscato G, Casolaro A, Ferdeghini M, Murri L, Ferrannini E (1999) Effect of 1\u2013year treatment with interferon\u2013beta1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur J Endocrinol 141:325\u2013331","journal-title":"Eur J Endocrinol"},{"key":"934_CR50","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(94)91339-0","volume":"344","author":"Moreau","year":"1994","unstructured":"Moreau T, Thorpe J, Miller D, Moseley I, Hale G, Waldmann H, Clayton D, Wing M, Scolding N, Compston A (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis [published erratum appears in Lancet 1994 Aug 13, 344(8920):486]. Lancet 344:298\u2013301","journal-title":"Lancet"},{"key":"934_CR51","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1046\/j.1471-4159.2001.00141.x","volume":"76","author":"Nicholas","year":"2001","unstructured":"Nicholas RS, Compston A, Brown DR (2001) Inhibition of tumour necrosis factor\u2013alpha (TNFalpha)\u2013induced NFkappaB p52 converts the metabolic effects of microglial\u2013derived TNFalpha on mouse cerebellar neurones to neurotoxicity. J Neurochem 76:1431\u20131438","journal-title":"J Neurochem"},{"key":"934_CR52","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1212\/WNL.53.4.751","volume":"53","author":"Paolillo","year":"1999","unstructured":"Paolillo A, Coles AJ, Molyneux P, Gawne Cain ML, MacManus D, Barker GJ, Compston A, Miller D (1999) Quantitative MRI in patients with secondary progressive multiple sclerosis treated with monoclonal antibody Campath\u20131H. Neurology 53:751\u2013757","journal-title":"Neurology"},{"key":"934_CR53","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1093\/brain\/120.12.2149","volume":"120","author":"Redford","year":"1997","unstructured":"Redford EJ, Kapoor R, Smith KJ (1997) Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 120:2149\u20132157","journal-title":"Brain"},{"key":"934_CR54","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1212\/WNL.54.5.1145","volume":"54","author":"Rice","year":"2000","unstructured":"Rice GP, Filippi M, Comi G (2000) Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54:1145\u20131155","journal-title":"Neurology"},{"key":"934_CR55","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/332323a0","volume":"332","author":"Riechmann","year":"1988","unstructured":"Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332:323\u2013327","journal-title":"Nature"},{"key":"934_CR56","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/BF03348040","volume":"21","author":"Rotondi","year":"1998","unstructured":"Rotondi M, Oliviero A, Profice P, Mone CM, Biondi B, Del Buono A, Mazziotti G, Sinisi AM, Bellastella A, Carella C (1998) Occurrence of thyroid autoimmunity and dysfunction throughout a nine\u2013month follow\u2013up in patients undergoing interferon\u2013beta therapy for multiple sclerosis. J Endocrinol Invest 21:748\u2013752","journal-title":"J Endocrinol Invest"},{"key":"934_CR57","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1523\/JNEUROSCI.16-16-05095.1996","volume":"16","author":"Sanchez","year":"1996","unstructured":"Sanchez I, Hassinger L, Paskevich PA, Shine HD, Nixon RA (1996) Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. J Neurosci 16:5095\u20135105","journal-title":"J Neurosci"},{"key":"934_CR58","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1212\/WNL.57.10.1888","volume":"57","author":"Simon","year":"2001","unstructured":"Simon JH, Jacobs L, Kinkel RP (2001) Transcallosal bands: a sign of neuronal tract degeneration in early MS? Neurology 57:1888\u20131890","journal-title":"Neurology"},{"key":"934_CR59","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1212\/WNL.57.10.1888","volume":"57","author":"Simon","year":"2001","unstructured":"Simon JH, Jacobs L, Kinkel RP (2001) Transcallosal bands: a sign of neuronal tract degeneration in early MS? Neurology 57:1888\u20131890","journal-title":"Neurology"},{"key":"934_CR60","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/ana.96","volume":"49","author":"Smith","year":"2001","unstructured":"Smith KJ, Kapoor R, Hall SM, Davies M (2001) Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 49:470\u2013476","journal-title":"Ann Neurol"},{"key":"934_CR61","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/brain\/awf015","volume":"125","author":"Stadelmann","year":"2002","unstructured":"Stadelmann C, Kerschensteiner M, Misgeld T, Bruck W, Hohlfeld R, Lassmann H (2002) BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 125:75\u201385","journal-title":"Brain"},{"key":"934_CR62","first-page":"898","volume":"Med","author":"The","year":"2000","unstructured":"The CHAMPS Study Group (2000) Intramuscular interferon beta\u20131a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898\u2013904","journal-title":"N Engl J"},{"key":"934_CR63","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","volume":"338","author":"Trapp","year":"1998","unstructured":"Trapp BD, Peterson J, Ransohoff RM, Rudick RA, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278\u2013285","journal-title":"N Engl J Med"},{"key":"934_CR64","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/107999002753536220","volume":"22","author":"Verdun","year":"2002","unstructured":"Verdun E, Isoardo G, Oggero A, Ferrero B, Ghezzi A, Montanari E, Zaffaroni M, Durelli L (2002) Autoantibodies in multiple sclerosis patients before and during IFN\u2013beta 1b treatment: are they correlated with the occurrence of autoimmune diseases? J Interferon Cytokine Res 22:245\u2013255","journal-title":"J Interferon Cytokine Res"},{"key":"934_CR65","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/brain\/112.6.1419","volume":"112","author":"Weinshenker","year":"1989","unstructured":"Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112:1419\u20131428","journal-title":"Brain"},{"key":"934_CR66","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/glia.1094","volume":"36","author":"Wilkins","year":"2001","unstructured":"Wilkins A, Chandran S, Compston A (2001) A role for oligodendrocytederived IGF\u20131 in trophic support of cortical neurons. Glia 36:48\u201357","journal-title":"Glia"},{"key":"934_CR67","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1523\/JNEUROSCI.23-12-04967.2003","volume":"23","author":"Wilkins","year":"2003","unstructured":"Wilkins A, Majed H, Layfield R, Compston A, Chandran S (2003) Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte\u2013derived glial cell linederived neurotrophic factor. J Neurosci 23:4967\u20134974","journal-title":"J Neurosci"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-005-0934-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-005-0934-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-005-0934-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T10:16:31Z","timestamp":1586340991000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-005-0934-5"}},"subtitle":["Evidence from monoclonal antibody therapy"],"short-title":[],"issued":{"date-parts":[[2005,7,27]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1007\/s00415-005-0934-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,27]]}}}